releases: https://bucshon.house.gov/news/documentsingle.aspx?DocumentID=3732
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://bucshon.house.gov/news/documentsingle.aspx?DocumentID=3732 | From the White House: House Drug Pricing Bill Could Keep 100 Lifesaving Drugs from American Patients | 2019-12-03 | 2019 | 2019-12 | Republican | House | IN | Larry Bucshon | B001275 | bucshon.house.gov | legacy | Washington, D.C.) Today, the White House released a statement outlining the devastating effects of H.R. 3, the Lower Drug Costs Now Act of 2019, Speaker Nancy Pelosi's top-down, heavy-handed government approach to reducing the cost of prescription drugs for the American people. The Trump Administration is committed to lowering prescription drug prices while encouraging medical innovation to help patients access new lifesaving drugs. H.R. 3, the Lower Drug Costs Now Act of 2019, may share the Trump Administration's first goal of lowering prices, but the threat it poses to continued medical innovation will harm American patients in ways that far outweigh any benefits. White House Full Press Release This heavy-hand government approach which will stymie the development of future cures is not the way to lower drug prices. I supported bipartisan solutions which Speaker Pelosi refuses to bring to the House floor in a way that can be signed into law. I will continue to work in a bipartisan way to get drug prices down for the American people. Dr. Bucshon Background Dr. Bucshon supported legislation to lower prescription drug costs that were passed out of the House Committee on Energy and Commerce in a bipartisan manner. CREATES Act - (H.R. 965) - Increases access to affordable prescription drugs by preventing pharmaceutical companies' bad behavior that delays access to generic competition. Pay for Delay - (H.R. 1499) Makes it illegal for brand-name drug manufacturers to pay generic manufacturers to keep generic prescription drugs off the market. Blocking Act - (H.R. 938) Expands access to generic prescription drugs by speeding up the introduction of generic drugs into the market. | 1 | 2026-03-30T12:14:52Z | 2026-03-30T12:14:52Z |